Tandem just got FDA approval for their t:slim x2 with BASAL-IQ and will be integrating the device with Dexcom G6. Sales will begin as early as August while expansion into several international markets is ongoing. In the meantime, we should expect to see FDA approval for Control-IQ in the first half of 2019. The company will reach cash break even point next year also. Technical chart should soon enter the previous falling wedge and hopefully break through it.